NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
66993-0845-35 | 66993-0845 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 1, 2020 | Sep 30, 2025 | In Use |
66993-0845-62 | 66993-0845 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 21, 2015 | Sep 30, 2021 | In Use |
66993-0846-35 | 66993-0846 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 30.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 1, 2020 | Sep 30, 2025 | In Use |
66993-0846-62 | 66993-0846 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 30.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 21, 2015 | Oct 31, 2021 | In Use |
67046-0683-30 | 67046-0683 | Finasteride | Proscar | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 14, 2018 | Feb 14, 2018 | No Longer Used |
67046-0695-30 | 67046-0695 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 30, 2018 | Sep 11, 2018 | No Longer Used |
67108-3565-09 | 67108-3565 | Mesna | Mesnex | 400.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Oral | Mar 21, 2002 | In Use | |
67157-0111-05 | 67157-0111 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | In Use | |||
67157-0111-25 | 67157-0111 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | Dec 2, 2016 | Dec 2, 2016 | In Use | |
67184-0501-01 | 67184-0501 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 11, 2016 | In Use | |
67184-0502-01 | 67184-0502 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 11, 2016 | In Use | |
67184-0503-01 | 67184-0503 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 11, 2018 | In Use | |
67184-0507-01 | 67184-0507 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 8, 2014 | In Use | |
67184-0507-05 | 67184-0507 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 8, 2014 | In Use | |
67184-0508-01 | 67184-0508 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 7, 2016 | In Use | |
67184-0509-01 | 67184-0509 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 7, 2016 | In Use | |
67184-0510-01 | 67184-0510 | Oxaliplatin | Oxaliplatin | 200.0 mg/40mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 7, 2016 | In Use | |
67184-0514-01 | 67184-0514 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 19, 2018 | In Use | |
67184-0515-02 | 67184-0515 | Palonosetron Hydrochloride | Palonosetron | 0.075 mg/1.5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 19, 2018 | In Use | |
67184-0531-01 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
67184-0531-02 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
67184-0531-03 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
67184-0532-01 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
67184-0532-02 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
67184-0532-03 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use |
Found 11120 results — Export these results